|Dr. Richard Spencer Treagus B.Sc., M.B.A., BScMed, MBChB, MPharmMed, MBA||Exec. Chairman||N/A||N/A||N/A|
|Mr. Lawrence Glass||Chief Science Officer||N/A||N/A||N/A|
|Mr. Jonathan Charles Pilcher||CFO & Company Sec.||N/A||N/A||N/A|
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. Its lead product is trofinetide, which has completed Phase II clinical trials for the treatment of Rett syndrome; is in Phase II clinical trials for the treatment of Fragile X syndrome; and conducted Phase II clinical trials for the treatment moderate to severe traumatic brain injury. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid syndrome. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.
Neuren Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.